View Future GrowthCalithera Biosciences 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Calithera Biosciences 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Dec 2022최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 15Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s DiseaseCalithera Biosciences, Inc. announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease. The Cala kIQ System delivers Cala TAPS (Transcutaneous Afferent Patterned Stimulation) therapy, which is validated by large clinical studies and real-world evidence demonstrating clinically meaningful tremor reduction and improvement in activities of daily living (ADLs). The Cala kIQ System empowers patients and physicians by providing an on-demand, comfortable, at-home therapy for ease of use and management of action hand tremors. This type of tremor occurs when the patient undergoes intentional movement or posture. Millions of people across the US live with essential tremor or Parkinson’s disease, and diagnoses continue to rise. Treatment options for these conditions have historically been medications or, in more severe cases – surgery. The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. The Cala kIQ System measures each patient's unique tremor physiology and individualizes a stimulation pattern for tremor relief. The system is designed to be easy to use for patients and easy to manage for clinicians. Therapy is on-demand for patients and delivered via a wrist-worn wearable. Designed with patients in mind for comfort and usability, the system also offers online data insights through the MyCala.com patient portal. Patients can see their therapy session results over time and choose to share with their providers to adjust treatment plans. Cala is committed to providing patients expanded access to Cala TAPS therapy. Cala is a contracted provider with major national and regional health plans for essential tremor including both commercial and Medical Advantage members. The Cala kIQ System is covered by the Veterans Affairs (VA) Health System at no cost to VA beneficiaries. Cala is working to secure additional coverage and reimbursement for the new breakthrough designated Parkinson's disease indication for the Cala kIQ System.공시 • Feb 03Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite IndexCalithera Biosciences, Inc. will be removed from the NASDAQ Composite Index.공시 • Jan 26Calithera Biosciences Board Approves Dissolution and LiquidationOn January 9, 2023, Calithera Biosciences, Inc. announced that its Board of Directors had unanimously approved the dissolution and liquidation of Calithera Biosciences pursuant to a plan of complete liquidation and dissolution, subject to stockholder approval. The company also announced, that in order to reduce costs and in connection with the planned dissolution, the company was discontinuing all clinical development programs and reducingour workforce, including the termination of most employees by the end of the first quarter. In light of planned dissolution, on January 24, 2023, the company received written notice from The Nasdaq Stock Market LLC, or Nasdaq, advising the company that based upon Nasdaq's review and pursuant to Listing Rule 5101, Nasdaq believes that the company is a public shell," and that the continued listing of the company's securities is no longer warranted. The company will not appeal Nasdaq's determination. Therefore, the company expects, based on Nasdaq's written notice, that the trading of the company's common stock will be suspended as of the opening of business on February 2, 2023, and that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the company's common stock from listing and registration on Nasdaq.공시 • Jan 10+ 2 more updatesCalithera Biosciences, Inc. Announces Executive DeparturesCalithera Biosciences, Inc. announced that in connection with the approval of the reduction-in-force, Eric Sjogren, Ph.D. company's Senior Vice President, Drug Discovery will be leaving Calithera Biosciences on February 3, 2023. Dr. Sjogren will be entitled to certain severance payments and the continuation of health benefits pursuant to the Calithera Biosciences, Inc. In connection with the reduction-in-force and wind up of company's operations, Susan M. Molineaux, Ph.D., company's President will also be leaving Calithera Biosciences as of future date to be determined, and will be entitled to certain severance payments and the continuation of health benefits pursuant to the Calithera Biosciences, Inc.Price Target Changed • Nov 16Price target decreased to US$12.36Down from US$30.00, the current price target is an average from 3 analysts. New target price is 419% above last closing price of US$2.38. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$5.24 next year compared to a net loss per share of US$31.16 last year.Seeking Alpha • Oct 03Calithera gains 16% as FDA awards Fast Track status for lung cancer candidateCalithera Biosciences, Inc. (NASDAQ:CALA) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA has offered the designation for sapanisertib to treat adults with unresectable or metastatic squamous non-small cell lung cancer with a particular genetic mutation in tumors and who have previously received chemotherapy and immune checkpoint inhibitors. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling the treatments to reach patients sooner. In July, CALA announced that the patient recruitment started in Phase 2 for sapanisertib (CB-228), designed to study the candidate in certain patients with squamous non-small cell lung cancer.Seeking Alpha • Aug 29Calithera rises 8% after HC Wainwright upgrades rating to buyCalithera Biosciences (NASDAQ:CALA) is trading ~8% higher after HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 2023. The company had cash and cash equivalents of $41.8M at June 30. Calithera has two ongoing clinical development programs that are expected to provide data updates in Q1 of 2023, Ramakanth tells investors in a research note. If positive, both drugs could be evaluated in registrational studies to achieve accelerated FDA approval, says the analyst. He estimates Calithera to achieve risk-adjusted revenues of $111M by 2030. (CALA) is down ~74% YTD.분석 기사 • Aug 17Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Price Target Changed • Apr 27Price target decreased to US$2.38Down from US$2.88, the current price target is an average from 4 analysts. New target price is 850% above last closing price of US$0.25. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$1.56 last year.분석 기사 • Dec 17We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Recent Insider Transactions • Nov 12Independent Director recently bought US$172k worth of stockOn the 10th of November, Jonathan Drachman bought around 200k shares on-market at roughly US$0.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months.분석 기사 • Aug 27We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Aug 03The Upcoming Calithera Cystic Fibrosis Data Could Be SignificantCalithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here could see a very strong stock appreciation, which currently the market may be overlooking.분석 기사 • May 02Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Executive Departure • Apr 06Chief Business Officer has left the companyOn the 2nd of April, Curtis Hecht's tenure as Chief Business Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Curtis' name. Curtis is the only executive to leave the company over the last 12 months.분석 기사 • Mar 10What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?If you want to know who really controls Calithera Biosciences, Inc. ( NASDAQ:CALA ), then you'll have to look at the...분석 기사 • Jan 17Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value EstimateIn this article we are going to estimate the intrinsic value of Calithera Biosciences, Inc. ( NASDAQ:CALA ) by taking...Is New 90 Day High Low • Jan 05New 90-day low: US$2.72The company is down 25% from its price of US$3.61 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$23.10 per share.Price Target Changed • Jan 05Price target lowered to US$10.10Down from US$11.50, the current price target is an average from 4 analysts. The new target price is 271% above the current share price of US$2.72. As of last close, the stock is down 47% over the past year.분석 기사 • Dec 13Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is New 90 Day High Low • Dec 11New 90-day high: US$5.03The company is up 39% from its price of US$3.63 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$17.34 per share.Is New 90 Day High Low • Nov 13New 90-day high: US$4.60The company is up 9.0% from its price of US$4.23 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$14.02 per share.Is New 90 Day High Low • Sep 24New 90-day low: US$3.43The company is down 35% from its price of US$5.28 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$18.23 per share.매출 및 비용 세부 내역Calithera Biosciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:CALA 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 220-2114030 Sep 220-84155130 Jun 227-85195131 Mar 2210-107195131 Dec 2110-115215130 Sep 2110-6822030 Jun 213-8020031 Mar 210-8621031 Dec 200-9020030 Sep 200-8919030 Jun 200-8718031 Mar 200-9117031 Dec 190-9017030 Sep 190-8815030 Jun 190-8614031 Mar 1917-6514031 Dec 1822-5513030 Sep 1830-4613030 Jun 1837-3313031 Mar 1827-3513031 Dec 1726-2813030 Sep 1719-2612030 Jun 1711-2911031 Mar 174-3411031 Dec 160-3811030 Sep 160-3710630 Jun 160-37101331 Mar 160-3491831 Dec 150-339030 Sep 150-31923양질의 수익: CALA가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 CALA의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 CALA의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: CALA의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: CALA의 지난 해 수익 증가율이 Biotechs 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: CALA는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/15 11:06종가2026/06/02 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Calithera Biosciences, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mohit BansalCitigroup IncMichael KingCitizens JMP Securities, LLCSwayampakula RamakanthH.C. Wainwright & Co.5명의 분석가 더 보기
공시 • Jun 15Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s DiseaseCalithera Biosciences, Inc. announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease. The Cala kIQ System delivers Cala TAPS (Transcutaneous Afferent Patterned Stimulation) therapy, which is validated by large clinical studies and real-world evidence demonstrating clinically meaningful tremor reduction and improvement in activities of daily living (ADLs). The Cala kIQ System empowers patients and physicians by providing an on-demand, comfortable, at-home therapy for ease of use and management of action hand tremors. This type of tremor occurs when the patient undergoes intentional movement or posture. Millions of people across the US live with essential tremor or Parkinson’s disease, and diagnoses continue to rise. Treatment options for these conditions have historically been medications or, in more severe cases – surgery. The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. The Cala kIQ System measures each patient's unique tremor physiology and individualizes a stimulation pattern for tremor relief. The system is designed to be easy to use for patients and easy to manage for clinicians. Therapy is on-demand for patients and delivered via a wrist-worn wearable. Designed with patients in mind for comfort and usability, the system also offers online data insights through the MyCala.com patient portal. Patients can see their therapy session results over time and choose to share with their providers to adjust treatment plans. Cala is committed to providing patients expanded access to Cala TAPS therapy. Cala is a contracted provider with major national and regional health plans for essential tremor including both commercial and Medical Advantage members. The Cala kIQ System is covered by the Veterans Affairs (VA) Health System at no cost to VA beneficiaries. Cala is working to secure additional coverage and reimbursement for the new breakthrough designated Parkinson's disease indication for the Cala kIQ System.
공시 • Feb 03Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite IndexCalithera Biosciences, Inc. will be removed from the NASDAQ Composite Index.
공시 • Jan 26Calithera Biosciences Board Approves Dissolution and LiquidationOn January 9, 2023, Calithera Biosciences, Inc. announced that its Board of Directors had unanimously approved the dissolution and liquidation of Calithera Biosciences pursuant to a plan of complete liquidation and dissolution, subject to stockholder approval. The company also announced, that in order to reduce costs and in connection with the planned dissolution, the company was discontinuing all clinical development programs and reducingour workforce, including the termination of most employees by the end of the first quarter. In light of planned dissolution, on January 24, 2023, the company received written notice from The Nasdaq Stock Market LLC, or Nasdaq, advising the company that based upon Nasdaq's review and pursuant to Listing Rule 5101, Nasdaq believes that the company is a public shell," and that the continued listing of the company's securities is no longer warranted. The company will not appeal Nasdaq's determination. Therefore, the company expects, based on Nasdaq's written notice, that the trading of the company's common stock will be suspended as of the opening of business on February 2, 2023, and that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the company's common stock from listing and registration on Nasdaq.
공시 • Jan 10+ 2 more updatesCalithera Biosciences, Inc. Announces Executive DeparturesCalithera Biosciences, Inc. announced that in connection with the approval of the reduction-in-force, Eric Sjogren, Ph.D. company's Senior Vice President, Drug Discovery will be leaving Calithera Biosciences on February 3, 2023. Dr. Sjogren will be entitled to certain severance payments and the continuation of health benefits pursuant to the Calithera Biosciences, Inc. In connection with the reduction-in-force and wind up of company's operations, Susan M. Molineaux, Ph.D., company's President will also be leaving Calithera Biosciences as of future date to be determined, and will be entitled to certain severance payments and the continuation of health benefits pursuant to the Calithera Biosciences, Inc.
Price Target Changed • Nov 16Price target decreased to US$12.36Down from US$30.00, the current price target is an average from 3 analysts. New target price is 419% above last closing price of US$2.38. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$5.24 next year compared to a net loss per share of US$31.16 last year.
Seeking Alpha • Oct 03Calithera gains 16% as FDA awards Fast Track status for lung cancer candidateCalithera Biosciences, Inc. (NASDAQ:CALA) added ~16% pre-market Monday after the oncology-focused biotech announced that the FDA issued the Fast Track designation for sapanisertib as a treatment for adults with a certain type of lung cancer. Specifically, the FDA has offered the designation for sapanisertib to treat adults with unresectable or metastatic squamous non-small cell lung cancer with a particular genetic mutation in tumors and who have previously received chemotherapy and immune checkpoint inhibitors. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling the treatments to reach patients sooner. In July, CALA announced that the patient recruitment started in Phase 2 for sapanisertib (CB-228), designed to study the candidate in certain patients with squamous non-small cell lung cancer.
Seeking Alpha • Aug 29Calithera rises 8% after HC Wainwright upgrades rating to buyCalithera Biosciences (NASDAQ:CALA) is trading ~8% higher after HC Wainwright upgrades rating to Buy to Neutral, with an $8 price target. HC Wainwright analyst Swayampakula Ramakant believes the company has sufficient cash to fund operations into Q2 of 2023. The company had cash and cash equivalents of $41.8M at June 30. Calithera has two ongoing clinical development programs that are expected to provide data updates in Q1 of 2023, Ramakanth tells investors in a research note. If positive, both drugs could be evaluated in registrational studies to achieve accelerated FDA approval, says the analyst. He estimates Calithera to achieve risk-adjusted revenues of $111M by 2030. (CALA) is down ~74% YTD.
분석 기사 • Aug 17Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Price Target Changed • Apr 27Price target decreased to US$2.38Down from US$2.88, the current price target is an average from 4 analysts. New target price is 850% above last closing price of US$0.25. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$1.56 last year.
분석 기사 • Dec 17We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Recent Insider Transactions • Nov 12Independent Director recently bought US$172k worth of stockOn the 10th of November, Jonathan Drachman bought around 200k shares on-market at roughly US$0.86 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months.
분석 기사 • Aug 27We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 03The Upcoming Calithera Cystic Fibrosis Data Could Be SignificantCalithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here could see a very strong stock appreciation, which currently the market may be overlooking.
분석 기사 • May 02Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Executive Departure • Apr 06Chief Business Officer has left the companyOn the 2nd of April, Curtis Hecht's tenure as Chief Business Officer ended after 2.2 years in the role. We don't have any record of a personal shareholding under Curtis' name. Curtis is the only executive to leave the company over the last 12 months.
분석 기사 • Mar 10What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?If you want to know who really controls Calithera Biosciences, Inc. ( NASDAQ:CALA ), then you'll have to look at the...
분석 기사 • Jan 17Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value EstimateIn this article we are going to estimate the intrinsic value of Calithera Biosciences, Inc. ( NASDAQ:CALA ) by taking...
Is New 90 Day High Low • Jan 05New 90-day low: US$2.72The company is down 25% from its price of US$3.61 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$23.10 per share.
Price Target Changed • Jan 05Price target lowered to US$10.10Down from US$11.50, the current price target is an average from 4 analysts. The new target price is 271% above the current share price of US$2.72. As of last close, the stock is down 47% over the past year.
분석 기사 • Dec 13Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Is New 90 Day High Low • Dec 11New 90-day high: US$5.03The company is up 39% from its price of US$3.63 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$17.34 per share.
Is New 90 Day High Low • Nov 13New 90-day high: US$4.60The company is up 9.0% from its price of US$4.23 on 14 August 2020. The American market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$14.02 per share.
Is New 90 Day High Low • Sep 24New 90-day low: US$3.43The company is down 35% from its price of US$5.28 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$18.23 per share.